Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
| 适应症 | Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma |
|---|---|
| 分期 | 2期 |
| 申办方 | HonorHealth Research Institute |
| 状态 | 已完成 |
| 受试者人数 | 19 人 |
| 干预（药物） | Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine |
| 开始日期 | 2020年12月1日 |
| 完成日期 | 2024年2月21日 |
| 结果公布日 | 2026年7月21日 |
摘要
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
CA 19-9 Normalization
| Treatment | 9.1 Percentage of participants |
|---|---|
| Treatment | 18.2 Percentage of participants |
| Treatment | 72.7 Percentage of participants |
| Treatment | 36.4 Percentage of participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group